Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Johnson

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
American Journal of Hematology|February 13, 2008
Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong KongGeoffrey T Gibney, Carolien I M Panhuysen, Jason C C So, et al.
NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
American Journal of Hematology|February 13, 2008
Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong KongGeoffrey T Gibney, Carolien I M Panhuysen, Jason C C So, et al.
NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Pageof 6